Evidence map›Paper›PMID 32679269›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice.

Xin Wei, Gang Zhao, Xiaobei Wang, Nagsen Gautam, Zhenshan Jia, Zhifeng Zhao, Dexuan Kong, Fan Zhang, Sushil Kumar, Yuanyuan Sun and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Xin WeiDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Gang ZhaoDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Xiaobei WangDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Nagsen GautamDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Zhenshan JiaDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Zhifeng ZhaoDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Dexuan KongDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Fan ZhangDepartment of Pharmacy Practice and Science, College of Pharmacy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Sushil KumarDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Yuanyuan SunDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Ningrong ChenDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Xiaoyan WangDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Libin YangDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Rongguo RenDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Geoffrey M ThieleDivision of Rheumatology, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Tatiana K BronichDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
James R O'DellDivision of Rheumatology, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Yazen AlnoutiDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Dong WangDepartment of Pharmaceutical Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: dwang@unmc.edu.
University of Nebraska Medical Center · USNebraska Medical Center · US

Funding

Nebraska Center for Nanomedicine- Pilot ProjectsP30GM127200 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2018 to 2022
$5.7M
Nanomedicine Development for Systemic Lupus ErythematosusR01AI119090 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, DONG · 2016 to 2020
$1.9M
NIAID NIH HHS R01 AI119090NIGMS NIH HHS P30 GM127200
6 · The paper itself

Abstract

HPMA copolymer-based dexamethasone prodrug (P-Dex) and PEG-based dexamethasone prodrug (PEG-Dex, ZSJ-0228) were previously found to passively target the inflamed kidney and provide potent and sustained resolution of nephritis in NZB/WF1 lupus-prone mice. While both prodrug nanomedicines effectively ameliorate lupus nephritis, they have demonstrated distinctively different safety profiles. To explore the underlining mechanisms of these differences, we conducted a head-to-head comparative PK/BD study of P-Dex and PEG-Dex on NZB/WF1 mice. Overall, the systemic organ/tissue exposures to P-Dex and Dex released from P-Dex were found to be significantly higher than those of PEG-Dex. The high prodrug concentrations were sustained in kidney for only 24 h, which cannot explain their lasting therapeutic efficacy (>1 month). P-Dex showed sustained presence in liver, spleen and adrenal gland, while the presence of PEG-Dex in these organs was transient. This difference in PK/BD profiles may explain PEG-Dex' superior safety than P-Dex.

Indexed as

AdenosineAnimalsDexamethasoneDisease Models, AnimalHumansKidneyLupus NephritisMiceMice, Inbred NZBNanomedicineNanoparticlesPolymersProdrugsSpleenTissue DistributionAdenosineDexamethasoneN(6)-(5-hydroxy-2-pyridyl)methyladenosinePolymersProdrugsDexamethasoneLupus nephritisP-DexPharmacokinetics and biodistributionProdrug nanomedicineZSJ-0228

Identifiers

PMID32679269
PMCPMC7508892
OpenAlexW3042352619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.